• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

    9.920 +0.790 (+8.65%)
    Streaming Delayed Price Updated: 12:14 PM EDT, Jun 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about ProMIS Neurosciences Inc. - Common Shares

    < Previous 1 2 3 4 5 Next >
    News headline image
    ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying ↗
     
    Via Benzinga
    News headline image
    Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying ↗
     
    Via Benzinga
    News headline image
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
    It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! 
    Via InvestorPlace
    News headline image
    Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024 ↗
    PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
     
    Via Benzinga
    News headline image
    ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 ↗
    PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    News headline image
    ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
    Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
    Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies 
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
    Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
    Via Benzinga
    News headline image
    Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings ↗
    U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also... 
    Via Benzinga
    Topics Stocks
    News headline image
    ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
    Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) 
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 ↗
    PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    News headline image
    ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
    Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
    Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease 
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
    Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies 
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    ProMIS Neurosciences Issues Letter to Shareholders
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    News headline image
    Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
    Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... 
    Via Benzinga
    News headline image
    ProMIS Neurosciences, Inc. Announces Leadership Transition
    Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer 
    From ProMIS Neurosciences Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.